Human metapneumovirus (hMPV), a virus that infects the upper and lower respiratory systems—leading to bronchitis and pneumonia in some patients—could soon meet its medical match. A scientific team in Texas, in collaboration with biotech companies, has made recent breakthroughs in understanding the virus, and their efforts could lead to everything from the first-ever vaccines against hMPV to new, highly effective therapeutics.
A dozen offerings from The University of Texas at Austin were ranked among the nation's best "Degrees of the Future 2022" by Gizmodo. The ranking came in a new special report from the technology, science and culture publication dedicated to "honoring the universities preparing students for tomorrow."
For more affordable, sustainable drug options than we have today, the medication we take to treat high blood pressure, pain or memory loss may one day come from engineered bacteria, cultured in a vat like yogurt. And thanks to a new bacterial tool developed by scientists at The University of Texas at Austin, the process of improving drug manufacturing in bacterial cells may be coming sooner than we thought.
An enzyme variant created by engineers and scientists at The University of Texas at Austin can break down environment-throttling plastics that typically take centuries to degrade in just a matter of hours to days.
John Wallingford, professor of molecular biosciences at The University of Texas at Austin, and his team used a process called live cell imaging to make observations about how a developing embryo transforms from its early ball shape into a more elongated shape with a distinct head and rear. Disruptions to this process in human embryos can lead to birth defects.
Read our publication, The Texas Scientist, a digest covering the people and groundbreaking discoveries that make the College of Natural Sciences one of the most amazing and significant places on Earth.
